Archive
Pharmacogenetics in oncology: a promising field.
Curr Pharm Des. 2010;16(2):155-63
Authors: Houtsma D, Guchelaar HJ, Gelderblom H
Pharmacogenetics is a rapidly developing field, especially in oncology. In the most ideal situation pharmacogenetics will allow oncologists to individualize therapy based on patients' individual germline genetic test results.
Pharmacogenetics in treatment of rheumatoid arthritis.
Curr Pharm Des. 2010;16(2):164-75
Authors: Kooloos WM, Huizinga TW, Guchelaar HJ, Wessels JA
Over the last decades important progress is being made regarding disease modifying anti-rheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis (RA).
Introducing pharmacy students to pharmacogenomic analysis.
Am J Pharm Educ. 2009 Jul 10;73(4):71
Authors: Krynetskiy E, Lee Calligaro I
OBJECTIVES: To implement and evaluate the effectiveness of a laboratory component involving deoxyribonucleic acid (DNA) testing to a required pharmacogenomics course.
Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism.
Lancet Oncol. 2010 Jun;11(6):507-9
Authors: Relling MV, Altman RB, Goetz MP, Evans WE
PMID: 20413348 [PubMed - indexed for MEDLINE]
Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities.
Med Decis Making. 2010 May-Jun;30(3):328-40
Authors: Conti R, Veenstra DL, Armstrong K, Lesko LJ, Grosse SD
Personalized medicine is health care that tailors interventions to individual variation in risk and treatment response. Although medicine has long strived to achieve this goal, advances in genomics promise to facilitate this process.
New Multiplex Panels from Aushon BioSystems Help Measure Urinary Biomarkers of Kidney Damage during Drug Development
Researchers can better determine risk while speeding the pace and increasing the accuracy of clinical phase research efforts
BILLERICA, Mass. , (July 1, 2010) – Aushon BioSystems, Inc. , a leading provider of advanced microarray instrumentation and laboratory services for biomarker discovery, development and analysis, has launched new Human multiplex biomarker panels for the quantification of eight biomarkers related to drug-induced kidney damage, or nephrotoxicity.
GeneNews Executes Marketing Partnership Agreement with GeneDiagnostics
GeneNews Limited (TSX: GEN), a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it has executed a formal marketing partnership agreement with GeneDiagnostics Inc. (“GD”) to market ColonSentry™, the world's first blood-based test to determine a person's current risk for colorectal cancer, in China.
As noted in a previous press release dated May 19, 2010, the agreement provides GD with non-exclusive rights to market and sell the ColonSentry™ test in Shanghai and the provinces of Zhejiang and Jiangsu.
Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy.
Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy.
Eur J Clin Pharmacol. 2010 Jun 27;
Authors: Gervasini G, BenÃtez J, Carrillo JA
Genetic factors contribute to the phenotype of drug response, but the translation of pharmacogenetic outcomes into drug discovery, drug development or clinical practice has proved to be surprisingly disappointing.